Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. ('Terns' or the 'Company') (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the appointment of Robert Azelby, a seasoned biotechnology executive and board director, to the Company's Board of Directors, effective immediately. In conjunction with Mr. Azelby's appointment, Carl Gordon is stepping down from the Board of Directors following more than seven years of service.
'I am thrilled to welcome Bob to the Terns Board as he brings extensive strategic and operational leadership across multiple therapeutic indications and stages of development. Bob's experience developing and commercializing important cancer treatments well positions him to provide guidance as we prepare TERN-701 for late-stage studies in chronic myeloid leukemia,' said Amy Burroughs, chief executive officer of Terns. 'We thank Carl for his many contributions to Terns' development over the past seven years. He has been foundational in establishing the Company from its earliest stages and supporting our evolution into a diversified company with multiple clinical programs.'
'I am pleased to be joining Terns as we advance our lead oncology and obesity programs towards important clinical readouts later this year,' said Mr. Azelby. 'I look forward to working with Terns' talented leadership and Board in advancing these potentially game-changing medicines for the patients who need them most.'
'Terns has come a long way since its inception in 2017 as a company focused on creating revolutionary small molecules with known underlying biology. I am proud of Terns' many accomplishments over the years, including its strategic leadership and continued clinical execution through challenging times. I remain confident that Terns is well-positioned for continued success as it advances its class leading programs forward,' added Dr. Gordon.
Mr. Azelby is an experienced chief executive officer and veteran board member who has spent more than 30 years in the biopharmaceutical industry. From October 2020 to February 2023, he served as president and chief executive officer of Eliem Therapeutics, Inc. Prior to that, Mr. Azelby served as the chief executive officer of Alder BioPharmaceuticals, Inc. from June 2018 until its acquisition by H. Lundbeck in 2019. From November 2015 to May 2018, Mr. Azelby served as executive vice president, chief commercial officer of Juno Therapeutics, Inc. Prior to that, Mr. Azelby served in various positions at Amgen Inc., including vice president and general manager, oncology, vice president, Amgen oncology sales, vice president, commercial effectiveness unit and general manager of Amgen Netherlands. Mr. Azelby currently serves on the board of directors of ADC Therapeutics, Autolus Therapeutics and Cardinal Health. He previously served on the board of directors of Eliem Therapeutics, Alder BioPharmaceuticals, Chinook Therapeutics, Clovis Oncology, Inc., Cascadian Therapeutics, Inc. and Immunomedics Inc. Mr. Azelby holds a B.A. in Economics and Religious Studies from the University of Virginia and an M.B.A. from Harvard Business School.
About Terns PharmaceuticalsTerns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns' pipeline contains three clinical stage development programs including an allosteric BCR-ABL inhibitor, a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator discovery effort, prioritizing a GIPR antagonist nomination candidate. For more information, please visit: www.ternspharma.com.
Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements about the Company within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding the Company's strategy, future financial condition, future operations, future trial results, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results and the implementation of the Company's plans to vary materially. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's SEC reports, including but not limited to its Annual Report on Form 10-K for the year ended December 31, 2023. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Contacts for Terns
InvestorsJustin Nginvestors@ternspharma.com
MediaJenna UrbanBerry & Company Public Relationsmedia@ternspharma.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
16 minutes ago
- Business Wire
Casey's Announces Timing of First Quarter Earnings Release and Conference Call
ANKENY, Iowa--(BUSINESS WIRE)--Casey's General Stores, Inc. ('Casey's' or the 'Company') (Nasdaq: CASY), one of the leading convenience store chains in the United States, will issue first quarter fiscal 2026 results after the market closes on September 8 th, 2025. Casey's will hold a conference call and webcast on Tuesday, September 9 th at 7:30am central to review the results. A live webcast of the event will be available on Casey's website on the Investor Relations page at For those unable to listen to the live broadcast, an audio replay will be available on Casey's for twelve months. Casey's is a Fortune 500 company (Nasdaq: CASY) operating approximately 2,900 convenience stores. Founded more than 50 years ago, the company has grown to become the third-largest convenience store retailer and the fifth-largest pizza chain in the United States. Casey's provides freshly prepared foods, quality fuel and friendly service at its locations. Guests can enjoy pizza, donuts, other assorted bakery items, and a wide selection of beverages and snacks. Learn more and order online at or in the mobile app. CASY-IR
Business Wire
16 minutes ago
- Business Wire
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Unicycive Therapeutics, Inc. ('Unicycive' or 'the Company') (NASDAQ: UNCY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 29, 2024 and June 27, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before October 14, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Unicycive overstated its ability to satisfy FDA manufacturing compliance requirements. The Company overstated the chances of FDA approval for OLC, its treatment for hyperphosphatemia in CKD patients on dialysis. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Unicycive, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
35 minutes ago
- Yahoo
Marvell Technology (MRVL) Stock Gains 10% as Microsoft AI Chip Potential Sparks Interest
Marvell Technology, Inc. (NASDAQ:MRVL) is one of the top stocks sold by hedge funds. On July 30, MRVL stock rose 10% following Fubon Research's emphasis on the company's strong revenue potential tied to Microsoft's AI chip developments. Fubon Research says Microsoft has upgraded the Maia300 chip, which Marvell is working on, from 3nm with HBM3E to a newer 2nm design with HBM4. This change has pushed production from early 2026 to late 2026, but analysts still see it as a big opportunity for Marvell. Copyright: ralwel / 123RF Stock Photo The Maia300 chip is set to start production in late 2026 with about 300,000 to 400,000 units, increasing to 1.2 to 1.5 million units in 2027. At an average price of $8,000 per chip, Fubon expects the project could bring in around $2.4 billion in 2026 and $10 to $12 billion in 2027. Analysts noted that Microsoft seems to have more confidence in Marvell's Maia300 than in its own Maia200 chip. This change comes as Microsoft is reportedly struggling with its in-house chip design, and Fubon believes the company will likely rely more on Marvell for its current chips. The research also pointed out that Microsoft has increased the 2026 production of its Maia200 chip from 40,000-60,000 units to 150,000-200,000 units to make up for the delayed launch of the Maia300. Fubon's report added that Microsoft might charge more than Amazon Web Services (AWS), as the Maia300 has an average price of $8,000, much higher than AWS Trainium 2's $1,500, even though both have similar margins of 55-60%. Marvell Technology, Inc. (NASDAQ:MRVL) delivers comprehensive semiconductor solutions across the data infrastructure spectrum, with a portfolio including system-on-a-chip architectures, Ethernet solutions, storage controllers, interconnect products, and different host system interfaces. While we acknowledge the potential of MRVL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Sign in to access your portfolio
